A Phase 3, Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Evaluate Efficacy and Safety of Mongersen GED-0301 Maintenance Therapy in Subjects With Crohn's Disease
Phase of Trial: Phase III
Latest Information Update: 05 Oct 2017
At a glance
- Drugs Mongersen (Primary)
- Indications Crohn's disease
- Focus Adverse reactions; Registrational
- Sponsors Celgene Corporation
- 29 Aug 2017 Planned End Date changed from 28 Oct 2022 to 31 Dec 2021.
- 29 Aug 2017 Planned primary completion date changed from 30 Sep 2022 to 30 Nov 2021.
- 23 May 2017 Planned number of patients changed from 1414 to 1300.